The gene-editing therapy OTQ923 normalized brain blood flow in 3 sickle cell disease patients, suggesting it may lower stroke ...

The first healthy volunteer has been dosed in a Phase 1 study of Cellarity's novel globin-switching therapy CLY-124 for ...

As a result of being a caregiver for her cousin, columnist Sylvia Amuta says she's now more caring, compassionate, and kind ...

Considering a change to your treatment regimen? Columnist Mary Shaniqua shares tips to help patients and providers make an ...

Higher pain scores upon discharge from the emergency department may predict hospitalization in adolescents with SCD, a study ...

As a result, recommendations on physical exercise for people with SCD remain unclear. To learn more, a group of researchers in Senegal set out to determine whether physical activity correlates with ...

To mark four years of sharing his experiences through writing, columnist Dunstan Nicol-Wilson reflects on the journey with gratitude.

BEAM-101, a treatment for sickle cell disease, showed sustained efficacy and safety over one year in the BEACON Phase 1/2 trial.